HIV and AIDS Articles
| |
FDA-approved
Treatments Experimental
Treatments
Top
New Articles
Guidelines |  |
GSK-364735 Resistance Profile of the Integrase Inhibitor S/GSK-364735 - 2/10/08 Integrase Inhibitor GSK364735 is Safe and Well-tolerated in Phase I Study - 3/06/07 A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor GSK364735 in Healthy Subjects (GRZ105655) S Reddy and others. Poster 562. Copyright GlaxoSmithKline. Used with permission, 2007. - 3/16/07
|
| ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
